Rıza Yıldırım

Rıza Yıldırım

Auto-generated profile, based on publicly available information

Rıza Yıldırım

Izmir City Hospital, Department of Pediatrics, Division of Pediatric Allergy and Immunology, Izmir, Turkey

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2026 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
RYRıza Yıldırım
Rıza Yıldırım
EYECE ŞENBAYKAL YİĞİT
ECE ŞENBAYKAL YİĞİT
IŞİkBal Nur Şafak
İkBal Nur Şafak
HDHatemi Esam Demirtaş
Hatemi Esam Demirtaş
İTİlke Taşkırdı
İlke Taşkırdı
TTTuba Tuncel
Tuba Tuncel

8 October 2026 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
RYRıza Yıldırım
Rıza Yıldırım
EYECE ŞENBAYKAL YİĞİT
ECE ŞENBAYKAL YİĞİT
IŞİkBal Nur Şafak
İkBal Nur Şafak
HDHatemi Esam Demirtaş
Hatemi Esam Demirtaş
APAyşe Pakel
Ayşe Pakel
TTTuba Tuncel
Tuba Tuncel

27 March 2024 in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
Verified
Journal Article
Open access
PDF file
ŞGŞule Gökçe
Şule Gökçe
MTMERVE TOSYALI
MERVE TOSYALI
AŞAykut Şafaklı
Aykut Şafaklı
RYRıza Yıldırım
Rıza Yıldırım
NANecla Burcu Koçer Ahmadov
Necla Burcu Koçer Ahmadov
FKFeyza Koc
Feyza Koc
Immune thrombocytopenia (ITP) is a reason of thrombocytopenia that is characterized by isolated thrombocytopenia in childhood. Epstein barr virus infection (EBV) is a mildly and uncomplicated ailment that might be a trigger factor for ITP. Here, we discuss two cases with ITP secondary Epstein barr virus infection.

11 September 2026 in Anatolian Current Medical Journal
Verified
Journal Article
Open access
IÇİsMail Çifçi
İsMail Çifçi
FGFeride Gülcüler
Feride Gülcüler
RYRıza Yıldırım
Rıza Yıldırım
TTTuba Tuncel
Tuba Tuncel
UGUmut Gök
Umut Gök
Aims: This study aims to evaluate the relationship between asthma self-efficacy levels and asthma control in adolescents aged 12-18 with physician-diagnosed asthma. Additionally, factors associated with asthma control status were examined.Methods: In this cross-sectional analytical study, 108 adolescents aged 12-18 years with at least one year of physician-diagnosed asthma were included. Data were collected using a sociodemographic and clinical information form, the Asthma Control Test (ACT), and the Adolescent Asthma Self-Efficacy Questionnaire (AASEQ). Those with an ACT score of 19 or lower were classified as not having well-controlled asthma, while those with an ACT score of 20 or higher were classified as having well-controlled asthma. Descriptive statistics, group comparisons, correlation analysis, and simple linear regression analysis were used for data analysis. A p-value of

23 October 2026 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
RYRıza Yıldırım
Rıza Yıldırım
HTHande Ilgaz Tüzen
Hande Ilgaz Tüzen
PYPelin Abdal Yıldırım
Pelin Abdal Yıldırım
EYECE ŞENBAYKAL YİĞİT
ECE ŞENBAYKAL YİĞİT
IŞİkBal Nur Şafak
İkBal Nur Şafak
TTTuba Tuncel
Tuba Tuncel

18 February 2026 in Klinische Padiatrie
Verified
Journal Article
Closed access
PDF file
RYRıza Yıldırım
Rıza Yıldırım
GOGulcihan Ozek
Gulcihan Ozek
EAEda Ataseven
Eda Ataseven
SASerap Aksoylar
Serap Aksoylar
Survival in high-risk neuroblastoma has improved with multimodal treatment approaches and numerous studies have focused on treatment-related side effects. This study examines the prevalence, severity and risks of late effects following high-dose chemotherapy and autologous stem cell transplantation in high risk neuroblastoma patients. This study included high-risk neuroblastoma patients who underwent autologous stem cell transplantation and survived 5 years without relapse in a single center. Of the 41 patients who received high-dose chemotherapy and autologous stem cell transplantation, 20 patients survived without relapse for at least 5 years and were included in the analysis. Amid 20 patients, 12 patients (60%) were men. The median age of the patients was 13.5 years at the last follow up. After six cycles of induction chemotherapy, 11 patients (55%) received busulfan–melphalan as the consolidation regimen, while 9 patients (45%) received carboplatin–etoposide–melphalan. The median follow-up after transplantation was 9 years. At least one complication occurred in 19 out of 20 patients (95%). Severe late complications were observed in seven patients. Two patients developed treatment-related secondary neoplasms. In contrast to the literature, the most common adverse event was focal nodular hyperplasia (40%) in the liver. The second most common adverse event was ovarian failure (37.5%) and the third most common was hearing loss (35%). Endocrine pathologies were more common in patients receiving busulfan–melphalan as the consolidation regimen. This study highlights the future risks of side effects in high-risk neuroblastoma survivors and emphasizes the need for a long-term follow-up.